Skip to content
DataLookout
Menu

Volido PASNCT07918443

Post-Approval Study of Saypha® ChIQ™ for Midface Augmentation in Subjects With Fitzpatrick Skin Types V and VI

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of treatment-emergent adverse events (TEAEs)
Timeframe: Baseline through Week 24 after the last injection

Secondary (9)

Injection site reactions
Subject-reported pain
Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on the evaluating investigator's live assessment
Responder status on the 5-point Midface Volume Deficit Severity Scale (MVDSS) based on independent photographic reviewers' assessment
Change from baseline in midface volume deficit measured by the 5-point Midface Volume Deficit Severity Scale (MVDSS), based on the evaluating investigator's live assessment
Show 4 moreShow less
Global aesthetic improvement based on the 5-point modified Global Aesthetic Improvement Scale (mGAIS)
Subject satisfaction with treatment outcome and appearance based on the FACE-Q™ "Satisfaction with Outcome" and "Satisfaction with Cheeks" questionnaires
Injection volume required to achieve optimal aesthetic correction
Change from baseline in nasolabial fold severity measured by the Nasolabial Fold Severity Rating Scale (NLF-SRS) based on the evaluating investigator's live assessment

Arms and interventions

saypha® ChIQ™Experimental

Participants receive treatment with saypha® ChIQ™ for correction of moderate to severe midface volume deficit. An optional touch-up treatment may be administered approximately 2 weeks after the initial treatment if clinically indicated.

Devices: Crosslinked hyaluronic acid dermal filler with lidocaine